Skip to main content
Equibles

NGEN · Nervgen Pharma Corp. · Metrics

Track NGEN — free

Use NGEN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NGEN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.19 +0.03 (+1.16%) At close · Sep 11
Rebalance outlook locked
Market Cap
$234.94M
Shares
107.52M

NGEN metrics

39 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$2.19
Market cap
$234.94M

Price action

20 metrics
Price change (1W)
-6.2%
Price change (30D)
+25.9%
Price change (3M)
+13.8%
Price change (6M)
-39.3%
Price change (YTD)
-61.0%
Price change (1Y)
-17.5%
Trailing year
Price change (5Y)
+32.4%
52-week high
$5.97
52-week low
$1.59
Change from 52-week high
-63.4%
Change from 52-week low
+37.4%
Annualized volatility
84.5%
Annualized volatility (3M)
57.7%
Beta
1.7
RSI (14D)
58.8
Price vs SMA 50
+16.1%
Price vs SMA 200
-35.1%
Avg volume (3M)
668,983
Relative volume
0.8
Average dollar volume
$1.30M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
107.52M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
92.7
reciprocal yield 1.1%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
—

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
—
Net income (TTM)
—
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.04

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
—
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-1,268.9%
Return on assets
-190.1%
Debt / equity
—
Current ratio
1.2
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
1.2
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$16.10M
Total assets
$16.93M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
—
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
64
13F filer change QoQ
+19
Institutional ownership
11.4%

Short interest

3 metrics
Short interest
5.1%
Latest settlement · 8.3 days to cover
Days to cover
8.3d
Short-squeeze score
73 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1751912 CUSIP 64082X203 13F (30d) 21 filings 21 filers Visit website